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Abstract Expression in Escherichia coli of Streptomyces acyl 
carrier proteins (ACPs) associated with polyketide biosynthesis 
using the pT7-7 expression system of Tabor and Richardson led 
to the production predominantly of inactive a/>o-proteins lacking 
the 4'-phosphopantetheinyl prosthetic group essential for poly-
ketide synthase activity. Modification of growth conditions led to 
an increase of production of active Ao/o-protein for the 
actinorhodin (act) ACP, but this technique was ineffective for 
oxytetracycline (otc) and griseusin (gris) ACPs. Labelling 
experiments revealed that a low level of otc ACP expressed 
prior to induction was produced mainly as active Aofo-protein, 
while post-induction 15N-labelled protein was almost exclusively 
in the apo-ACP form. Limiting endogenous Ao/o-acyl carrier 
protein synthase (ACPS) concentration was implicated as 
responsible for low apo-ACP to holo-ACP conversion, rather 
than limiting substrate (coenzyme A) and cofactor (Mg2+) 
concentrations. Co-expression of act and gris ACPs with ACPS 
in E. coli led to high levels of production of active holo- ACPs and 
ACPS. We have also made the significant observation that 
ACPS is able to transfer acylated CoA moieties to act apo-ACP. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Polyketides form a large and diverse group of secondary 
metabolites produced by plants, fungi, marine organisms 
and bacteria (Fig. 1) [1]. Amongst bacteria the Actinomycetes 
have been the chief source of pharmacologically active poly-
ketide antibiotics such as oxytetracycline (otc), tetracenomy-
cin (tcm) and erythromycin (ery). The biosynthesis of these 
compounds and others such as actinorhodin (act) [2] have 
been studied in depth and shown to closely resemble fatty 
acid biosynthesis. The carbon backbones of both polyketides 
and fatty acids are built up by iterative decarboxylative con-
densations of an acyl chain with acetate derived malonate 
units [3]. During fatty acid biosynthesis the growing acyl chain 
is covalently linked to an acyl carrier protein (ACP). The acyl 
group is bound as a thiol ester to the terminal thiol of a 4'-
phosphopantetheine prosthetic group which in turn is cova-
lently bound to the hydroxyl of a conserved serine residue. 
This is also the case for polyketide biosynthesis where one or 
more ACPs are required for each polyketide synthase (PKS). 
In E. coli the 4'-phosphopantetheine prosthetic group is at-
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tached to the conserved serine of fatty acid synthase (FAS) 
ACP by holo-ACP synthase (ACPS), utilising coenzyme A 
(CoA) in a Mg2+-dependent reaction [4,5]. 
As part of ongoing investigations of PKS ACP structure 
and function, we have been expressing individual PKS genes 
from the genetic clusters associated with the biosynthesis of 
act, otc and griseusin (gris). We engineered the first few co-
dons of each Streptomyces ACP gene to reflect the codon 
preferences of E. coli (Table 1). Using this strategy each of 
the genes was expressed in E. coli, using the pT7-7 heat-induc-
ible system of Tabor and Richardson [6], to provide sufficient 
quantities of act, otc and gris ACPs for preliminary character-
isation [7]. We have also recently reported preliminary [8] and 
full [9] tertiary structures of act apo-ACP. Although we ob-
tained satisfactory yields of expressed protein (ca 10-30 mg 
1_1), the ACPs were obtained in predominantly their inactive 
apo-form, lacking the 4'-phosphopantetheine prosthetic 
group. Active holo-ACP formed little (0-10%) of the total 
purified protein. This low level of holo-ACP could be in-
creased in the case of act ACP by increasing the post-induc-
tion incubation time from 2 h to 6 h, such that up to 40% of 
the isolated protein was in the active holo-form [7]. However, 
this increase in the proportion of holo-ACP was accompanied 
by a fall in the total ACP recovered, possibly reflecting pro-
teolytic degradation. In the case of gris and otc ACPs, holo-
protein is not usually observed under our standard production 
conditions. Low levels of conversion of apo to holo-ACP have 
also previously been observed for expression of tcm ACP in E. 
coli [10]. 
In order to facilitate our continuing studies of ACP struc-
ture and function we set out to investigate the reasons for, 
and to attempt to remedy, the low conversions of PKS apo to 
holo-ACPs when expressed by E. coli. 
2. Materials and methods 
2.1. 13JV labelling of otc ACP 
E. coli K38 pGPl-2 containing pIJ5231, a derivative of pT7-7 con-
taining otc-ACP between initial Ndel and terminal BamHl sites, was 
grown to an A5g5 of 1.5 in 25 X 100 ml sterile LB medium containing 
appropriate antibiotics. Cells were spun down (7000 rpm, 15°C, 15 
min, Sorval GS3 rotor) and resuspended in 100 ml sterile M9 minimal 
medium. Cells were again pelleted and resuspended in 100 ml sterile 
M9 minimal medium. Aliquots of 5 ml were used to inoculate 25 X 100 
ml of sterile M9 minimal medium containing 1.0 g 1_1 '"NFLtCl and 
appropriate antibiotics in 500 ml flasks. Induction was performed 
immediately by heating the flasks to 42°C for 30 min and growth 
was continued at 30°C for 18 h. Otc ACP was purified as previously 
described [7]. 
2.2. Cloning and expression 
E. coli strains were DH5a which was used for standard cloning 
procedures, and K38 containing pGPl-2 (KmR) used for expression 
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of cloned genes. Standard cloning procedures [11] were adopted unless 
otherwise stated. Expression and purification of ACPs, SDS PAGE 
and electrospray mass spectrometry were performed as described pre-
viously [7]. The synthesis of acpS was achieved by polymerase chain 
reaction (PCR) using E. coli DH5a chromosomal DNA as a template, 
with the following synthetic oligonucleotides: a 37-mer 5'-AGATC-
TAAGGAGATATACTAATGGCAATATTAGGTTT-3'; and a 26-
mer, 5'-AGATCTTTAACTTTCAATAATTACCG-3'. Each oligonu-
cleotide incorporated a BglU restriction site at its 5' terminus, and the 
37-mer incorporated a ribosome binding site (RBS, underlined) posi-
tioned 8 bases upstream from the initial ATG codon. The PCR (100 
ul) contained 1 U of Vent DNA polymerase (New England Biolabs), 
6 mM MgSC>4, 1 pM of each oligonucleotide, a small amount of lysed 
DH5a and other reagents as specified by the suppliers. The temper-
ature program was 96°C for 60 s, then 55°C for 45 s, then 72°C for 60 
s, repeated 25 times, then cooled to 4°C. A PCR product of the 
expected 408 bp was precipitated from the reaction, then resuspended 
in water and treated with T4 polynucleotide kinase and ATP at 37°C 
for 1 h. Phosphorylated DNA was purified by electrophoresis in 2% 
low melting point agarose, followed by elution according to the meth-
od of Boyle and Lew [12] into 25 ill H 2 0 . The phosphorylated PCR 
product was ligated into the dephosphorylated Smal site of pBlue-
script SK(+) using T4 DNA ligase. The sequence of one clone was 
confirmed by double-strand sequencing using T3 and T7 primers. The 
cloned gene and RBS were then excised (BgKI) and sub-cloned into 
the BamHI sites of pIJ2366, a derivative of pT7-7 containing actl-
ORF3 (C17S), and into pIJ5235, a derivative of pT7-7 containing 
gra-ORF3 [13]. Positive clones were identified by restriction analysis 
and a positive representative of each was designated pRJCOOl (act) 
and pRJC002 (gris); these were subsequently transformed into the 
expression host K38 pGPl-2. 
2.3. Assay of holo-ACP and ACPS 
The viability of the purified act holo-ACP was assessed by its ability 
to act as an acceptor of 14C-labelled malonyl groups from 14C-malon-
yl CoA catalysed by cloned and expressed (R.J. Cox and T.S. Hitch-
man, unpublished results) S. coelicolor malonyl CoA: ACP transacy-
lase (MCAT) using previously published protocols [7,14]. 
Holo-ACP synthase activity was measured using the following assay 
system. E. coli strains K38 pGPl-2 and K38 pGPl-2 pRJCOOl were 
grown to A595 1.5 at 30°C in LB medium containing appropriate 
antibiotics. Induction of £ coli K38 pGPl-2 pRJCOOl was performed 
by heating to 42°C for 30 min, followed by incubation at 30°C for 2 h. 
ACPS containing protein extracts were prepared by breaking the cells 
(sonication) and removing cell debris by centrifugation. Protein con-
centration (Bradford) was adjusted to 44 u.g jj.1 x by dilution as nec-
essary. Assays were performed at 37°C for 30 min in a final volume of 
20 ul. The assay contained purified act apo-ACP (C17S, 50 uM), 
[14C]acetyl CoA (25 uM, 56 mCi mmol"1), Mg2+ (10 mM), Tris pH 
8.8 (50 mM) and an aliquot (10 ul) of the crude protein fraction 
containing ACPS. ACP was precipitated by the addition of bovine 
serum albumin (50 ug) and trichloroacetic acid (50%, 30 ul). Pellets 
were washed with trichloroacetic acid (50%, 3x50 ul) and resus-
pended in 2 M Tris (50 |xl) then dissolved in scintillant (Packard, 10 
ml). The amount of precipitated act [14C]acetyl-/!o/o-ACP was deter-
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Fig. 1. Structures of aromatic polyketides produced by type II poly-
ketide synthases. 
mined by scintillation counting for 1 min. Results (Fig. 4) are quoted 
as an average of three parallel assays. 
3. Results and discussion 
Our previous work has shown that wild-type act holo-ACP 
is prone to dimerisation through disulphide formation of cys-
teine-17 [7]. This residue also forms an internal disulphide 
with the terminal thiol of the 4'-phosphopantetheine pros-
thetic group (J. Crosby, K. Byrom and H.C.O Brown, unpub-
lished results). These problems were overcome by replacing 
cysteine-17 with serine. The C17S mutant was expressed 
from pIJ2366 (R. Cox, J. Crosby and K. Byrom, unpublished 
results). This protein is expressed at similar levels (10-15 mg 
1_1) to the wild-type act ACP in E. coli. The protein was 
purified from E. coli K38 pGPl-2 pIJ2366 by initial ammo-
nium sulphate precipitation. A sodium chloride gradient was 
then used to elute bound proteins from a Q-Sepharose anion 
exchange FPLC column (Pharmacia). ACP was eluted as two 
peaks at approximately 500 mM NaCl (Fig. 2A). Analysis of 
the major peak by electrospray mass spectrometry (ESMS) 
gave a mass of 9101 Da indicative of act apo-ACP minus 
the N-terminal methionine residue (Fig. 2C, Table 2). Similar 
analysis of the minor peak (10-15% of the major peak) gave a 
mass of 9444 Da corresponding to act holo-ACP, again minus 
the N-terminal methionine (Fig. 2D). Otc and gris ACPs were 
Table 1 
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Fig. 2. Purification and ESMS analysis of act ACP. A: Q-Sepharose FPLC trace of E. coli protein fraction containing act ACP expressed from 
pIJ2366. B: Q-Sepharose FPLC trace of E. coli protein fraction containing act ACP expressed from pRJCOOl. C: ESMS of act apo-ACP, note 
distinctive envelope of Na+ adducts. D: ESMS of act holo-ACP, again showing Na+ adducts. 
similarly expressed from pIJ5231 and pIJ5235. Under condi-
tions comparable to the act ACP expression, apo-gris and apo-
otc ACPs were produced with no observable amounts of the 
holo-form of either. Thus the ability of the expressed ACPs to 
act as substrates for the endogenous E. coli ACPS appeared to 
be limited. 
One possible cause of low ACP conversion was low intra-
cellular concentrations of the substrate (CoA) and cofactor 
(Mg2+) required by ACPS. A similar effect has been observed 
by Chapman-Smith et al. who found that ATP concentrations 
were limiting for the conversion of highly expressed apo-biotm 
carboxy carrier protein to its biotinylated holo-form by biotin 
ligase in E. coli [15]. We thus examined whether the supple-
mentation of additional substrate and cofactor, CoA and 
Mg2+ respectively, to a cell-free extract of heat-shocked E. 
Table 2 



































9 678 ±3.8 
10 020 ±4.3 
9 549 ±4.0 
9 879 ±4.0 
9914±3.1 
10255± 1.3 
10 026 ±3.8 
10 367 ±3.8 
"ACPs are observed to have retained their initial methionine residues 
unless otherwise indicated. 
coli K38 pGPl-2 pIJ2366 could facilitate conversion of the 
act apo-ACP to the holo-form. Thus lysed suspensions of 
the induced strain in the presence of protease inhibitors 
were incubated at 37°C with added CoA (50-250 uM) and 
Mg2+ (5-25 uM) for 30 min. Subsequent purification of act 
ACP in the usual way revealed no increase in the concentra-
tion of holo-ACP with respect to controls. Thus it appeared 
that intra-cellular substrate CoA and Mg2+ concentrations 
were not limiting for the conversion of heterologous PKS 
apo to holo-ACPs in E. coli. The results of Leadlay et al. 
would appear to support this hypothesis. They showed that 
the heterologous expression of a presumed FAS ACP from 
the Actinomycete Saccharopolyspora erythrae in E. coli 
yielded high levels (20 mg 1_1) of predominantly (65%) holo-
ACP [16,17]. Clearly in this case CoA and Mg2+ cannot be 
limiting. This is in agreement with the recent observations of 
Cronan et al. who showed that under usual conditions in vivo 
CoA concentrations are high enough to ensure full conversion 
of endogenous E. coli ACP to Ao/o-protein [18]. 
We obtained further information about the activity of 
ACPS as a result of an experiment to produce quantities of 
otc ACP highly enriched in 15N for NMR studies. Thus we 
grew E. coli K38 pGPl-2 pIJ5231 in LB medium at 30°C to 
mid-log phase. The cells were washed, then transferred to M9 
minimal medium containing 15NH4C1, and immediately in-
duced by heat shock to 42°C for 30 min. Subsequent growth 
at 30°C for 18 h, followed by purification of otc ACP, re-
vealed that two otc ACP peaks eluted from the Q-Sepharose 
FPLC column (Fig. 3A). These were analysed by ESMS. As 
expected the first peak contained otc apo-ACP (18 mg 1_1) in 
15N-labelled form with mass of 10026 Da (10031 Da pre-
dicted for all 115 N-positions 15N-labelled, Fig. 3B). This 
fraction contained a trace amount ( < 1% of the major 
peak) of unlabelled apo-ACP (measured mass 9914 Da, calcu-
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Fig. 3. Purification and ESMS analysis of otc ACP after growth and induction in minimal medium containing 15NH4C1. A: Q-Sepharose 
FPLC trace of E. coli protein fraction containing otc ACP expressed from pIJ5231. B: ESMS of [15N]otc apo-ACP, note distinctive envelope 
of Na + adducts. C: ESMS of [15N]otc holo-ACP, again showing Na + adducts as well as a significant proportion of unlabelled otc holo-ACP. 
lated 9916 Da). The second fraction eluted from the FPLC 
column contained labelled otc holo-ACP (4 mg 1_1) with a 
mass of 10367 Da (10 376 Da predicted for all 115 N posi-
tions labelled, Fig. 3C). Significantly this species contained 
approximately 10% (ca 0.4 mg 1_1) of a species of otc holo-
ACP containing no 15N label with a mass of 10256 Da (10256 
Da predicted for otc holo-ACP). 
The long post-induction period, possibly coupled with a 
difference in media composition, led in this case to the pro-
duction of otc holo-ACP at a similar level (10%) to that ob-
served for the production of act holo-ACP under short (2 h) 
post-induction conditions. Significantly however, since label-
ling and induction were performed simultaneously, unlabelled 
protein must have been produced prior to addition of label 
and concomitant induction. Of the unlabelled protein, ca 0.18 
mg 1_1 was apo-ACP, while ca 0.4 mg 1_1 was holo-ACP. At 
least 60% of the protein produced prior to induction was 
therefore holo-ACP, contrasting with only 10% holo-ACP 
formed after induction. This observation may possibly be in-
terpreted as evidence for substrate inhibition of ACPS, since 
1000 
Fig. 4. Results of ACPS activity assay using purified act apo-ACP, [14C]acetyl CoA and cell free extracts of the indicated E. coli strains. Condi-
tions are described in Section 2. 
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Fig. 5. Q-Sepharose FPLC trace of E. coli protein fraction containing gris ACP expressed from pRJC002. 
ACPS appears to be able to convert the low concentration of 
otc ACP (ca 0.4 mg 1_1) produced prior to induction, but was 
unable to cope with high levels (ca 18 mg 1_1) of otc apo-ACP 
expressed after induction. This observation is consistent with 
that of Walsh et al. who have isolated the E. coli ACPS and 
shown that E. coli apo-ACP binds tightly to ACPS with a sub-
micromolar Km [19,20]. Indeed, substrate inhibition was ob-
served at concentrations of apo-ACP above 2 uM. 
Our results, and those of Hutchinson [10], show that the 
type II PKS ACPs are clearly poor in vivo substrates for the 
endogenous E. coli ACPS. This contrasts with the S. erythrae 
FAS ACP which appears to be a relatively good in vivo sub-
strate of E. coli ACPS [16,17]. In addition otc ACP could also 
cause substrate inhibition. We reasoned that an increase of in 
vivo ACPS concentration should allow partial or full conver-
sion of apo- to /zo/otype II PKS ACPs. The expression vectors 
pIJ2366 and pIJ5235 contain ac?I-ORF3 from Streptomyces 
coelicolor and gris-OKF3 from S. griseus respectively between 
initial Ndel and terminal Bamlil sites, downstream from T7 
promoters. Construction of operons containing ACP ORFs 
and acpS should ensure synthesis of both proteins at similar 
levels, thus increasing the rate of apo- to hob-ACP conversion 
and overcoming any potential substrate inhibition of endoge-
nous ACPS. Walsh and co-workers have recently reported the 
cloning of the E. coli ACPS gene, acpS (previously dpf) 
[19,20]. A synthetic acpS was therefore constructed in which 
the leading and trailing sequences contained convenient BgM 
restriction sites. The leading sequence also contained a ribo-
some binding site 8 base-pairs upstream of the initial ATG 
codon. This construct was inserted at the BamYLI sites of 
pIJ2366 and pIJ5235 to create pRJCOOl and pRJC002 respec-
tively. Restriction analysis confirmed that the cloning had 
occurred in the correct direction. 
The expression of pRJCOOl and pRJC002 in E. coli K38 
pGPl-2 was performed as usual. For pRJCOOl SDS PAGE 
analysis (data not shown) of induced and uninduced cultures 
showed the presence of two proteins of apparent Mw 14 kDa 
and 4 kDa corresponding to ACPS and act ACP respectively 
in the induced lysates. Purification of act ACP from an in-
duced culture in the usual way again gave two peaks from the 
Q-sepharose column corresponding to act ACP (Fig. 2B). 
ESMS analysis of these fractions indicated that the ACP 
was now present in >90% holo-fovm. Overall total protein 
synthesis mirrored the previously observed concentration of 
ca 10-15 mg 1_1. The two proteins expressed from pRJCOOl 
were assayed to ensure that activity was retained using this 
system. Firstly the ability of purified act holo-ACP to accept 
14C-labelled malonyl groups from [14C]malonyl CoA, cata-
lysed by purified Streptomyces coelicolor MCAT [7,14], was 
confirmed. Secondly we examined the activity of ACPS, using 
a modified version of the assay of Vagelos et al. [4,5]. This 
assay consists of monitoring the transfer of 3H-labelled phos-
phopantetheine from CoA to apo-ACP. Crude protein frac-
tions containing ACPS were obtained from E. coli K38 pGPl-
2 and from induced E. coli K38 pGPl-2 pRJCOOl. ^ - L a -
belled CoA was unavailable to us, and we reasoned that 
ACPS was unlikely to discriminate the distal thiol group of 
CoA and may utilise [14C]acetyl CoA with similar efficiency. 
We were pleased to observe that acetyl CoA is indeed a sub-
strate for ACPS in an assay containing ACPS, purified act 
apo-ACP and [14C]acetyl CoA. Considerably higher activities 
of ACPS were observed in lysates from induced E. coli K38 
pGPl-2 pRJCOOl than from the control strain (Fig. 4). 
Although the protein extract isolated from the induced culture 
of E. coli K38 pGPl-2 pRJCOOl was some 8-fold more active 
than the control strain in the ACPS assay, only 0.8% of the 
available act apo-ACP was converted to act [14C]acetyl-/io/o-
ACP under the assay conditions. 
Similar expression of pRJC002 followed by standard puri-
fication revealed two protein peaks eluted from the Q-Sephar-
ose FPLC column in approximately 2:3 ratio (Fig. 5). Anal-
ysis of the peaks by SDS PAGE and ESMS (data not shown) 
confirmed that they were holo- and apo-forms of gris ACP. 
Interestingly ESMS analysis also revealed that each species 
was a 1:1 mixture of forms with and without the N-terminal 
methionine. In accord with our previous observations total 
gris ACP concentration was ca 6-8 mg 1_1. Attempts to in-
crease the proportion of gris holo-ACP through increased 
post-induction time were successful. However, as we have 
previously observed, longer post-induction times lead to sig-
nificant loss of total ACP protein. 
These results indicate that increased levels of ACPS in vivo 
can overcome the slow transformation of heterologous PKS 
apo-ACPs to the phosphopantetheinylated /w/o-form, sup-
porting our hypothesis that PKS ACPs are poor substrates 
of the endogenous E. coli ACPS. In particular the 15N label-
ling experiment suggests that high levels of expressed heterol-
ogous apo-ACPs may also inhibit endogenous ACPS in agree-
ment with the previous observations of Walsh et al. with E. 
coli FAS-ACP [19,20]. Although over 90% of act ACP was 
converted to holo-ACP when co-expressed with ACPS, it ap-
peared that under similar conditions gris ACP was more 
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poorly converted. However, this is the first time that we have 
observed gris holo-ACP. This technique represents a signifi-
cant advance in our ability to produce active Ao/o-proteins for 
our continuing studies of P K S A C P structure and function. 
We have also made the significant observation that ACPS is 
able to transfer acylated CoA moieties to act apo-ACP. This 
methodology is currently being applied to the production of 
other P K S hoIo-ACPs, and exploitation of the ability of 
ACPS to transfer acylated phosphopantetheine moieties to 
apo-ACPs, as a route to the study of the 3D structure of 
acylated holo-ACPs, is being pursued. 
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